OptimizeRx Corp.
- OPRX ยท Nasdaq
- Services-Business Services, NEC
- Waltham, MA
- 104 employees
- CIK 0001448431
Updated from SEC filings through
Top things to know
Executives
- Stephen L. Silvestro Chief Executive Officer 4, 2026-08-24
- Andrew D'Silva Chief Financial Officer 8-K, 2026-08-12
- Andrew J. D'Silva Chief Business Officer 4, 2026-09-02
-
Brendan W. Merrell CHIEF OPERATING OFFICER 4, 2026-08-24 -
Edward Stelmakh Chief Finance & Strat Officer 4, 2026-08-24 -
Marion Odence-Ford Chief Legal & Admin Officer 4, 2026-08-24
OptimizeRx Corp is a U.S. public company in services-business services, nec (SIC 7389), headquartered in Waltham, MA. It trades as OPRX on Nasdaq. Revenue was $109M in the fiscal year ending December 31, 2025, +18.8% from the year before. It reported about 104 employees. Stephen L. Silvestro is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $109M 10-K, 2026-03-12 | $92.1M 10-K, 2026-03-12 | $71.5M 10-K, 2025-03-20 | $62.5M 10-K, 2024-04-15 | $61.3M 10-K, 2023-03-10 |
| Operating income | $11.7M 10-K, 2026-03-12 | -$13.7M 10-K, 2026-03-12 | -$26.4M 10-K, 2025-03-20 | -$12.3M 10-K, 2024-04-15 | $361K 10-K/A, 2023-03-10 |
| SG&A | Not on file | Not on file | Not on file | $33.5M 10-K, 2023-03-10 | $27.7M 10-K, 2023-03-10 |
| Net income | $5.1M 10-K, 2026-03-12 | -$20.1M 10-K, 2026-03-12 | -$17.6M 10-K, 2025-03-20 | -$11.4M 10-K, 2024-04-15 | $378K 10-K, 2023-03-10 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Stephen L. Silvestro CEO at OptimizeRx Corporation- Transforming the way manufacturers engage with doctors and patients to drive better outcomes and reduce waste in the system | Chief Executive Officer | 4, 2026-08-24 |
| Stephen Silvestro | Named in proxy bio: Chief Executive Officer | DEF 14A, 2026-04-30 |
| Andrew D'Silva Chief Business Officer at OptimizeRx Corporation | Chief Financial Officer | 8-K, 2026-08-12 |
| Andrew J. D'Silva | Chief Business Officer | 4, 2026-09-02 |
| Brendan W. Merrell | CHIEF OPERATING OFFICER | 4, 2026-08-24 |
| Edward Stelmakh | Chief Finance & Strat Officer | 4, 2026-08-24 |
| Marion Odence-Ford Chief Legal & Administrative Officer | Chief Legal & Admin Officer | 4, 2026-08-24 |
| Heather Favazza | Chief Accounting Officer | 8-K, 2026-08-12 |
| Theresa Greco | Chief Commercial Officer | 4, 2026-05-18 |
| Brendan Merrell | Chief Operating Officer | 10-K, 2026-03-12 |
| Doug Besch | Chief Product & Technology Officer | 10-K, 2026-03-12 |
| Gregory Wasson | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
| Lynn O'Connor Vos | Board member (per proxy) bio: Chairperson of the OptimizeRx Board of Directors | DEF 14A, 2026-04-30 |
| Patrick Spangler | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
What OptimizeRx Corp does
OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers. We leverage our proprietary technology solutions and partnerships to help our clients develop and execute highly individualized and targeted marketing campaigns to drive physician and patient engagement and to enhance patient care.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 18.8 million (as of July 30, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $241M (as of June 30, 2025) | 10-K, March 12, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
| Latest proxy statement | Meeting June 9, 2026 (filed April 30, 2026) | DEF 14A, April 30, 2026 |
| Auditor | Uhy LLP (Sterling Heights, Michigan) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| December 19, 2025 | Edward Stelmakh Chief Finance & Strat Officer | Sale | 1,388 | $19K | Form 4, December 22, 2025 |
| October 3, 2025 | Stephen L. Silvestro Chief Executive Officer | Sale | 1,620 | $30K | Form 4, October 7, 2025 |
| August 28, 2025 | Patrick D. Spangler Director | Sale | 11,120 | $194K | Form 4, September 11, 2025 |
Recent 8-K events
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-12
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-05
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-12
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-04-09
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-30
- Item 4.01 Changes in registrant's certifying accountant
- 8-K filed 2026-03-05
- Item 1.01 Entry into a material definitive agreement
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 8.01 Other events
- 8-K filed 2025-11-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-08-19
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-08-07
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about OptimizeRx Corp
- What does OptimizeRx Corp do?
- In its own words, from Item 1 of its 10-K: "OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers. We leverage our proprietary technology solutions and partnerships to help our clients develop and execute highly individualized and targeted marketing campaigns to drive physician and patient engagement and to enhance patient care."
- What is OptimizeRx Corp's revenue?
- $109M for the fiscal year ending December 31, 2025, from its 10-K filed March 12, 2026.
- Is OptimizeRx Corp profitable?
- OptimizeRx Corp reported net income of $5.1M for the fiscal year ending December 31, 2025.
- How many employees does OptimizeRx Corp have?
- About 104 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of OptimizeRx Corp?
- Stephen L. Silvestro, Chief Executive Officer, as named in a 4 filed August 24, 2026.
- Who is the CFO of OptimizeRx Corp?
- Andrew D'Silva, Chief Financial Officer, as named in a 8-K filed August 12, 2026.
- Where is OptimizeRx Corp headquartered?
- Waltham, MA.
- What is OptimizeRx Corp's stock ticker?
- OPRX on Nasdaq.
- What industry is OptimizeRx Corp in?
- Services-Business Services, NEC, SIC code 7389.
- What is OptimizeRx Corp's website?
- optimizerx.com.
- When does OptimizeRx Corp report earnings next?
- November 11, 2026. Source: pg_earnings_events.
- Is OptimizeRx Corp a public company?
- Yes. OptimizeRx Corp files with the SEC under CIK 0001448431 and trades as OPRX.
- Who audits OptimizeRx Corp?
- Uhy LLP, Sterling Heights, Michigan, as named in its latest annual report (10-K).
- How many shares of OptimizeRx Corp are outstanding?
- 18.8 million shares as of July 30, 2026, from its 10-Q filed August 13, 2026.
- What is OptimizeRx Corp's public float?
- $241M as of June 30, 2025, as reported on the cover of its 10-K filed March 12, 2026.
- How many business segments does OptimizeRx Corp report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- When is OptimizeRx Corp's annual shareholder meeting?
- June 9, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.
- Have OptimizeRx Corp insiders traded stock recently?
- Since August 28, 2025, officers and directors reported 3 open-market sales worth about $244K and 0 purchases on Forms 4 and 5. The most recent: Edward Stelmakh (Chief Finance & Strat Officer) sold 1,388 shares on December 19, 2025.